Meitheal Pharmaceuticals is growing its specialty biopharmaceutical portfolio through a licensing agreement for a novel antibiotic approved to treat community-acquired bacterial pneumonia. The Chicago ...

Dr. Lonnie Brent appointed Senior Vice President of Medical Affairs Key leadership announcements reflect Meitheal’s growth trajectory – including major role of infectious disease medicines – and ...

Meitheal Pharmaceuticals has gotten federal approval for a new kind of antibiotic for use on hospitalized patients with urinary tract infections, a major step in the Chicago biopharma company's ...

Xentria’s bid to find a new use for TNF inhibitors has landed it with $45 million in the bank. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal ...

Meitheal Pharmaceuticals recently launched two new generics. The company released alprostadil injection 500 mcg/ml single-dose vials to the U.S. market, where only an ampoule form is offered. The ...

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured ...

Meitheal has expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., to market and distribute three biosimilars ...

Generic drug maker Meitheal Pharmaceuticals recalled one lot of cisatracurium besylate, a muscle relaxant, after what the Institute for Safe Medication Practices ...

CHICAGO, July 31, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization ...